Medivation Reports Second Quarter Financial Results and Provides Corporate Update

Medivation Reports Second Quarter Financial Results and Provides Corporate 
Update 
$82.4 Million in Second Quarter U.S. Net Sales; Conference Call Today
at 4:30 p.m. Eastern Time 
SAN FRANCISCO, CA -- (Marketwired) -- 08/08/13 --  Medivation, Inc.
(NASDAQ: MDVN) today provided a corporate update and reported its
financial results for the second quarter ended June 30, 2013. U.S.
net sales of XTANDI(R) (enzalutamide) capsules for the quarter, as
reported by Astellas Pharma Inc., were $82.4 million. The first
quarter net sales of $75.4 million included a favorable gross-to-net
adjustment of $4.4 million relating to prior periods. Ex-U.S. net
sales of XTANDI for the quarter, as reported by Astellas, were $3.7
million. XTANDI was granted marketing authorization in the European
Union in June 2013. 
"The European Union's recent decision to grant XTANDI marketing
authorization marks an important milestone as access to XTANDI begins
to expand beyond the United States," said David Hung, M.D., president
and chief executive officer of Medivation, Inc. "Medivation and
Astellas also achieved significant clinical milestones for XTANDI
during the quarter by completing enrollment in the Phase 2 TERRAIN
trial evaluating enzalutamide head-to-head versus bicalutamide and
initiating a Phase 2 trial in androgen receptor positive,
triple-negative breast cancer, where there is a significant unmet
need. We and Astellas look forward to the results of the interim
analysis for PREVAIL, our Phase 3 trial in men with advanced prostate
cancer who have not yet received chemotherapy, which will occur in
2013." 
Recent Developments  
XTANDI(R) (enzalutamide) capsules 


 
--  U.S. net sales of XTANDI were $82.4 million in the second quarter of
    2013. XTANDI was approved by the U.S. Food and Drug Administration on
    August 31, 2012 and was made available for shipment on September 13,
    2012. Medivation and Astellas are jointly responsible for
    commercialization and development of XTANDI in the U.S. and share
    equally in the costs (subject to certain exceptions), profits and
    losses arising from U.S. development and commercialization of XTANDI.
    
    
--  Ex-U.S. net sales of XTANDI were $3.7 million in the second quarter of
    2013. Outside the U.S., Astellas has respon
sibility for developing and
    commercializing XTANDI and pays Medivation a tiered royalty ranging
    from the low teens to the low twenties on aggregate net sales of
    XTANDI. XTANDI was granted marketing authorization in the European
    Union in June 2013 for the treatment of adult men with metastatic
    castration-resistant prostate cancer whose disease has progressed on
    or after docetaxel therapy. The European marketing approval triggered
    a $15 million milestone payment to Medivation during the second
    quarter under its collaboration agreement with Astellas.
    
    
--  Received marketing approval for XTANDI in Canada and South Korea for
    the post-chemotherapy indication.
    
    
--  Filed for marketing approval for XTANDI in Japan in May 2013, and was
    subsequently granted priority review, which reduces the agency's
    review time to approximately nine months. The Japanese filing
    triggered a $5 million milestone payment to Medivation during the
    second quarter under its collaboration agreement with Astellas.
    
    
--  Submitted applications to market XTANDI for the post-chemotherapy
    indication in Argentina, Australia, Brazil, South Africa and
    Switzerland.

  
Enzalutamide Clinical Development Program 


 
--  Exceeded the protocol-specified number of radiographic
    progression-free survival (PFS) events for the final analysis of the
    Phase 3 PREVAIL trial, and plan on conducting an interim overall
    survival (OS) analysis in 2013. The PREVAIL trial is evaluating
    enzalutamide versus placebo in 1,717 men with metastatic
    castration-resistant prostate cancer (mCRPC) who have not yet received
    chemotherapy. The co-primary endpoints in this trial are OS and PFS.
    Enrollment in this trial was completed in May 2012.
    
    
--  Advanced the development program comparing enzalutamide's effects on
    progression-free-survival when compared head-to-head versus
    bicalutamide, the most commonly used anti-androgen, in men who have
    progressed following medical castration with LHRH analog therapy or
    surgical castration.
    
    
    --  Completed patient enrollment in the TERRAIN trial, which enrolled
        approximately 370 men with metastatic disease primarily in Europe;
        and
        
    --  Continued patient enrollment in the STRIVE trial, which is
        enrolling approximately 400 men with either metastatic or
        non-metastatic disease primarily in the U.S.
        
        
--  Enrolled the first patient in a Phase 2 clinical trial evaluating
    enzalutamide as a single agent for the treatment of advanced, androgen
    receptor (AR)-positive, triple-negative breast cancer (TNBC). The
    Phase 2 open label, single-arm, multicenter trial plans to enroll
    approximately 80 patients with AR-positive, TNBC at sites in the
    United States, Canada and Europe. The primary endpoint of the trial is
    clinical benefit rate, defined as the proportion of patients with a
    best response of complete response, partial response or stable disease
    at ≥ 16 weeks.

  
Corporate Developments 


 
--  Hired Stephen M. Kelsey, M.D., F.R.C.P., F.R.C.Path. for the
    newly-created position of senior vice president of new projects. Dr.
    Kelsey's primary responsibility will be to drive new product
    candidates into clinical development. He was previously with Geron
    Corporation and Genentech.
    
    
--  Elected Dawn Graham and Wendy L. Yarno to the Medivation Board of
    Directors. Ms. Graham is the retired president of Europe and Canada at
    Merck & Co., Inc. Ms. Yarno is the retired chief marketing officer
    of Merck.

  
Second Quarter Financial Results 
XTANDI U.S. net sales for the second quarter of 2013, as reported by
Astellas, were $82.4 million compared to $75.4 million in the first
quarter of 2013. The first quarter net sales of $75.4 million
included a favorable gross-to-net adjustment of $4.4 million relating
to prior periods. Ex-U.S. net sales of XTANDI, as reported by
Astellas, were $3.7 million in the second quarter of 2013.
Medivation's collaboration revenue was $70.1 million for the second
quarter of 2013, which consists of three components: collaboration
revenue attributable to U.S. XTANDI net sales ($41.2 million),
collaboration revenue attributable to ex-U.S. XTANDI sales ($480
thousand) and collaboration revenue attributable to up-front and
development milestone payments ($28.5 million).  
Total operating expenses for the quarter ended June 30, 2013 were
$70.1 million, compared with total operating expenses of $43.9
million for the same period in 2012. These figures include non-cash
stock-based compensation expense of $8.1 million in the quarter ended
June 30, 2013, compared with $5.6 million for the same period in
2012. 
Medivation reported a net loss of $4.9 million, or $0.07 per diluted
share, for the quarter ended June 30, 2013, compared with a net loss
of $5.5 million, or $0.08 per diluted share, for the same period in
2012, adjusted on a post-split basis.  
At June 30, 2013, cash, cash equivalents and short-term investments
totaled $245.9 million, compared with $296.2 million at December 
31,
2012.  
2013 Financial Outlook 
For the full year 2013, Medivation expects U.S. net sales of XTANDI,
as reported by Astellas, to be in the range of $345-365 million.
Medivation continues to expect total operating expenses, net of
cost-sharing payments from Astellas, to be between $285 million and
$300 million.  
Conference Call Information 
To participate by telephone in today's live call beginning at 4:30
p.m. Eastern Time, please call 877-303-2523 from the U.S. or
+1-253-237-1755 internationally. Individuals may access the live
audio webcast by visiting http://investors.medivation.com/events.cfm.
A replay of the webcast will be available on the Company's website
for a limited time following the live event. 
About XTANDI  
Please visit www.XtandiHCP.com for full Prescribing Information for
XTANDI(R) (enzalutamide) capsules, including precautions, warnings,
adverse reactions, and contraindications for the treatment of
patients with metastatic castration resistant prostate cancer who
have previously received docetaxel. 
About XTANDI(R) (enzalutamide) capsules  
XTANDI is indicated for the treatment of patients with metastatic
castration-resistant prostate cancer (mCRPC) who have previously
received docetaxel. 
Important Safety Information for XTANDI
 Contraindications- XTANDI
can cause fetal harm when administered to a pregnant woman based on
its mechanism of action. XTANDI is not indicated for use in women.
XTANDI is contraindicated in women who are or may become pregnant. 
Warnings and Precautions- In the randomized clinical trial, seizure
occurred in 0.9% of patients on XTANDI. No patients on the placebo
arm experienced seizure. Patients experiencing a seizure were
permanently discontinued from therapy. All seizures resolved. 
Patients with a history of seizure, taking medications known to
decrease the seizure threshold, or with other risk factors for
seizure were excluded from the clinical trial. Because of the risk of
seizure associated with XTANDI use, patients should be advised of the
risk of engaging in any activity where sudden loss of consciousness
could cause serious harm to themselves or others. 
Adverse Reactions- The most common adverse drug reactions (≥
5%) reported in patients receiving XTANDI in the randomized clinical
trial were asthenia/fatigue, back pain, diarrhea, arthralgia, hot
flush, peripheral edema, musculoskeletal pain, headache, upper
respiratory infection, muscular weakness, dizziness, insomnia, lower
respiratory infection, spinal cord compression and cauda equina
syndrome, hematuria, paresthesia, anxiety, and hypertension. Grade
1-4 neutropenia occurred in 15% of XTANDI patients (1% Grade 3-4) and
in 6% on placebo (no Grade 3-4). Grade 1-4 elevations in bilirubin
occurred in 3% of XTANDI patients and 2% on placebo. One percent of
XTANDI patients compared to 0.3% on placebo died from infections or
sepsis. Falls or injuries related to falls occurred in 4.6% of XTANDI
patients vs 1.3% on placebo. Falls were not associated with loss of
consciousness or seizure. Fall-related injuries were more severe in
XTANDI patients and included non-pathologic fractures, joint
injuries, and hematomas. Grade 1 or 2 hallucinations occurred in 1.6%
of XTANDI patients and 0.3% on placebo, with the majority on
opioid-containing medications at the time of the event. 
Drug Interactions:- Effect of Other Drugs on XTANDI: Administration
of strong CYP2C8 inhibitors can increase the plasma exposure to
XTANDI. Co-administration of XTANDI with strong CYP2C8 inhibitors
should be avoided if possible. If co-administration of XTANDI cannot
be avoided, reduce the dose of XTANDI. Co-administration of XTANDI
with strong or moderate CYP3A4 and CYP2C8 inducers can alter the
plasma exposure of XTANDI and should be avoided if possible.  
Effect of XTANDI on Other Drugs: XTANDI is a strong CYP3A4 inducer
and a moderate CYP2C9 and CYP2C19 inducer in humans. Avoid CYP3A4,
CYP2C9 and CYP2C19 substrates with a narrow therapeutic index, as
XTANDI may decrease the plasma exposures of these drugs. If XTANDI is
co-administered with warfarin (CYP2C9 substrate), conduct additional
INR monitoring.  
For Full Prescribing Information, please visit www.XtandiHCP.com.  
About Medivation  
Medivation, Inc. is a biopharmaceutical company focused on the rapid
development of novel therapies to treat serious diseases for which
there are limited treatment options. Medivation aims to transform the
treatment of these diseases and offer hope to critically ill patients
and their families. For more information, please visit us at
www.medivation.com. 
The statements in this press release under the caption "2013
Financial Outlook" as well as statements regarding the timing of the
PREVAIL interim analysis are forward-looking statements that are made
pursuant to the safe harbor provisions of the federal securities
laws. Forward-looking statements involve risks and uncertainties that
could cause Medivation's actual results to differ significantly from
those projected, including, without limitation: risks related to the
timing, progress and results of Medivation's clinical trials,
including the risk that adverse clinical trial results could alone or
together with other factors result in the delay or discontinuation of
the commercialization of XTANDI or some or all of Medivation's
product development activities; Medivation's dependence on the
efforts of and funding by Astellas for the commercialization of
XTANDI; the risk of unanticipated expenditures or liabilities; and
other risks detailed in Medivation's filings with the Securities and
Exchange Commission, or SEC, including its quarterly report on Form
10-Q for the quarter ended June 30, 2013, which is expected to be
filed on August 8, 2013 with the SEC. You are cautioned not to place
undue reliance on the forward-looking statements, which speak only as
of the date of this release. Medivation disclaims any obligation or
undertaking to update, supplement or revise any forward-looking
statements contained in this press release. 


 
                                                                            
                                                                            
                              MEDIVATION, INC.                              
                        CONSOLIDATED BALANCE SHEETS                         
              (in thousands, except share and per share data)               
                                (unaudited)                                 
                                                                            
                                                                            
                                                June 30,      December 31,  
                                                  2013            2012      
                                             --------------  -------------- 
ASSETS                                                                      
Current assets:                                                             
  Cash and cash equivalents                  $      100,987  $       71,301 
  Short-term investments                            144,956         224,939 
  Receivable from collaboration partner              64,319          35,458 
  Restricted cash                                       343             343 
  Prepaid expenses and other current assets          14,711          12,175 
                                             --------------  -------------- 
                                                                            
    Total current assets                            325,316         344,216 
Property and equipment, net                          16,324          13,262 
Restricted cash, net of current                       9,899           8,843 
Other non-current assets                              6,369           5,545 
                                             --------------  -------------- 
                                                                            
Total assets                                 $      357,908  $      371,866 
                                             ==============  ============== 
                                                                            
LIABILITIES AND STOCKHOLDERS' EQUITY                                        
Current liabilities: 
                                                       
  Accounts payable                           $        3,944  $        2,073 
  Accrued expenses and other current                                        
   liabilities                                       57,485          48,951 
  Deferred revenue                                   25,396          33,862 
                                             --------------  -------------- 
                                                                            
    Total current liabilities                        86,825          84,886 
Convertible Notes, net of unamortized                                       
 discount of $56,774 and $62,743 at June 30,                                
 2013 and December 31, 2012, respectively           201,976         196,007 
Deferred revenue, net of current                         --           8,465 
Other non-current liabilities                         7,475           8,863 
                                             --------------  -------------- 
                                                                            
    Total liabilities                               296,276         298,221 
Commitments and contingencies                                               
Stockholders' equity:                                                       
  Preferred stock, $0.01 par value per share;                               
   1,000,000 shares authorized; no shares                                   
   issued and outstanding                                --              -- 
  Common stock, $0.01 par value per share;                                  
   170,000,000 shares authorized; 75,095,615                                
   and 74,774,939 shares issued and                                         
   outstanding at June 30, 2013 and December                                
   31, 2012, respectively                               751             748 
  Additional paid-in capital                        384,485         364,412 
  Accumulated other comprehensive income                 12              33 
  Accumulated deficit                              (323,616)       (291,548)
                                             --------------  -------------- 
                                                                            
    Total stockholders' equity                       61,632          73,645 
                                             --------------  -------------- 
                                                                            
Total liabilities and stockholders' equity   $      357,908  $      371,866 
                                             ==============  ============== 
                                                                            
                                                                            
                                                                            
                                                                            
                              MEDIVATION, INC.                              
                   CONSOLIDATED STATEMENTS OF OPERATIONS                    
                   (in thousands, except per share data)                    
                                (unaudited)                                 
                                                                            
                                                                            
                               Three Months Ended       Six Months Ended    
                                    June 30,                June 30,        
                             ----------------------  ---------------------- 
                                2013        2012        2013        2012    
                             ----------  ----------  ----------  ---------- 
Collaboration revenue        $   70,149  $   42,912  $  116,303  $   79,737 
Operating expenses:                                                         
  Research and development                                                  
   expenses                      28,205      21,550      53,113      41,580 
  Selling, general and                                                      
   administrative expenses       41,890      22,337      85,458      38,024 
                             ----------  ----------  ----------  ---------- 
                                                                            
    Total operating expenses     70,095      43,887     138,571      79,604 
                             ----------  ----------  ----------  ---------- 
                                                                            
Income (loss) from operations        54        (975)    (22,268)        133 
Other income (expense), net:                                                
  Interest expense               (4,982)     (4,688)     (9,870)     (5,273)
  Interest income                    52          56         126          83 
  Other income (expense), net        10          83           9         (15)
                             ----------  ----------  ----------  ---------- 
                                                                            
    Total other income                                                      
     (expense), net              (4,920)     (4,549)     (9,735)     (5,205)
                             ----------  ----------  ----------  ---------- 
                                                                            
Net loss before income tax                                                  
 (expense) benefit               (4,866)     (5,524)    (32,003)     (5,072)
Income tax (expense) benefit        (32)         24         (65)         12 
                             ----------  ----------  ----------  ---------- 
                                                                            
Net loss                     $   (4,898) $   (5,500) $  (32,068) $   (5,060)
                             ==========  ==========  ==========  ========== 
                                                                            
Basic and diluted net loss                                                  
 per common share            $    (0.07) $    (0.08) $    (0.43) $    (0.07)
                             ==========  ==========  ==========  ========== 
                                                                            
Weighted average common                                                     
 shares used in the                                                         
 calculation of basic and                                                   
 diluted net loss per common                                                
 share                           75,013      72,770      74,919      72,339 
                             ==========  ==========  ==========  ========== 

  
Contacts:
Patrick Machado
Chief Business & Financial Officer
(415) 829-4101 
Anne Bowdidge
Sr. Director, Investor Relations
(650) 218-6900